COMP <GO>
GPCR vs INVA // EV/EBITDA & P/E VALUATION
Structure Therapeutics Inc. (NASDAQ) VS. Innoviva Inc. (NASDAQ) • 15-METRIC TALLY: GPCR 1
— INVA 4
■ METRIC PARITY
LAST: $21.94 (+2.14%) • MKT CAP: $1.56B
valuation
—
LAST: $21.31 (+0.90%) • MKT CAP: $1.54B
valuation
7.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GPCR VS. INVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GPCR | INVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 74.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -19.50% | 14.70% | -34.20 | INVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 7.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -14.43% | 12.72% | -27.15 | INVA | /fcf-yield <GO> |
| Operating Margin | — | 39.80% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 14.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 6/9 | -5.00 | INVA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.5 | 53.4 | -26.88 | INVA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.56B | $1.54B | $25.0M | GPCR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GPCR REV | INVA REV | GPCR GROSS % | INVA GROSS % | GPCR FCF | INVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $411.3M | — | 74.8% | -$225.8M | $195.8M |
| FY 2024 | $0 | $358.7M | — | 82.6% | -$117.9M | $188.4M |
| FY 2023 | $0 | $310.5M | — | — | -$79.5M | $141.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GPCR // BETA —
INVA // BETA —